Dopamine
Approved · EMAAlso known as 3-Hydroxytyramine, 4-(2-aminoethyl)catechol, 4-(2-aminoethyl)pyrocatechol, Oxytyramine+7 more
3-Hydroxytyramine, 4-(2-aminoethyl)catechol, 4-(2-aminoethyl)pyrocatechol, Oxytyramine, Dopamina, 2-(3,4-dihydroxyphenyl)ethylamine, 3,4-Dihydroxyphenethylamine, 4-(2-Aminoethyl)benzene-1,2-diol, 4-(2-aminoethyl)-1,2-benzenediol, DOPamine Hydrochloride, Dopaminum.
Recent clinical, regulatory, research and industry developments relating to this drug.
A synaptic mechanism for encoding the learned value of action-derived safety.
The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise
Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson's Disease.
Cortical beta oscillations map to shared brain networks modulated by dopamine.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of hypotension in haemodynamically unstable neonates, infants and children < 18 years
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise
Decision Support for Intraoperative Low Blood Pressure
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences5
- The Journal of neuroscience : the official journal of the Society for Neuroscience5
- The Journal of clinical investigation3
- eLife2
- Journal of Parkinson's disease2
- Nature communications2
- Calabresi P2
- di Porzio U2
- Lin Y2
- Mercuri NB2
- Neumann WJ2
- Patriarchi T2
- Rodríguez-Oroz MC2
- Shi Z2
- Albert Einstein College of Medicine2
- Charité - Universitätsmedizin Berlin2
- Howard Hughes Medical Institute2
- School of Medicine and Surgery2
- University of California2
- University of Toronto2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Dopamine in the shared literature.
Studied across 3 of the same disease areas as Dopamine in the shared literature.
Studied across 3 of the same disease areas as Dopamine in the shared literature.
Studied across 2 of the same disease areas as Dopamine in the shared literature.
Studied across the same disease area as Dopamine in the shared literature.
Studied across the same disease area as Dopamine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.